S3V Vascular Technologies Limited Unlisted Share Price
As of , the indicative unlisted share price of S3V Vascular Technologies Limited is ₹545 per share. This is an over-the-counter reference price, not a stock-exchange quote.
As of , S3V Vascular Technologies Limited is not listed on any Indian stock exchange (NSE or BSE) — its shares trade in the unlisted, over-the-counter (pre-IPO) market.
| Price / unit | ₹545 |
|---|---|
| Market cap | ₹1,064 Cr |
| Min. investment | ₹10,900 |
| Lot size | 20 |
| P/E ratio | 18500 |
| P/B ratio | 7.56 |
What is S3V Vascular Technologies Limited?
S3V Vascular Technologies Limited is an unlisted Healthcare company whose shares trade in India's over-the-counter (pre-IPO) market and settle in demat form (NSDL/CDSL).
S3V Vascular Technologies Limited is an Indian medical device company that develops and manufactures advanced cardiovascular and critical-care products. Incorporated in 2011 and headquartered in Mysore, Karnataka, the company operates a fully integrated model that combines in-house research and development, proprietary engineering, and regulated manufacturing facilities. This vertical integration allows S3V to design, build, and validate its devices domestically rather than relying on imported components, which has historically been a hallmark of the Indian interventional cardiology market. The company's product portfolio spans drug-eluting stents, bare-metal stents, self-expanding stents, PTCA and neurovascular catheters, balloon dilatation catheter systems, aspiration catheters, and esophageal and biliary stents. Flagship lines include the 3V-KROME cobalt-chromium coronary stent system and the 3V-PAULO balloon dilatation catheter, both of which have carried CE approval. S3V has also pursued frontier products such as an indigenous mechanical thrombectomy device for stroke treatment, a bioabsorbable drug-coated stent, and a balloon-expandable transcatheter aortic valve replacement (TAVR) system, positioning itself across coronary, peripheral, neurovascular, and structural-heart segments. S3V traces its origins to a group of founders from the Indian School of Business, and its promoter team includes engineers with long backgrounds in indigenous cardiac stent development in India. The company has raised capital across multiple funding rounds from a broad investor base to support its research pipeline and manufacturing expansion. In the unlisted market, S3V Vascular Technologies draws attention as a domestic medical-technology manufacturer operating in a sector with high regulatory barriers and import-substitution relevance. Interest is also linked to its reported intent to pursue a public listing, which places it among pre-IPO names that market participants track. Its shares are held privately and quoted on an over-the-counter, indicative basis, with prices varying across counterparties based on supply and demand. As with all unlisted securities, liquidity is limited and valuations are subject to negotiation and change.
Explore more unlisted shares
Other companies in our curated selection.
Frequently asked questions
No. As of 16 July 2026, S3V Vascular Technologies Limited is an unlisted company whose shares trade over-the-counter; it would list only if and when it completes an IPO.
The minimum lot is 20 share(s); at the indicative price of about ₹545, that is approximately ₹10,900. Indicative reference, not a quote.
As of 16 July 2026, the indicative unlisted share price of S3V Vascular Technologies Limited is ₹545 per share. This is an over-the-counter reference price, not a stock-exchange quote.
The ISIN of S3V Vascular Technologies Limited is INE0HGT01012. An ISIN is the unique 12-character code that identifies a company's shares in the depository system; this one is verified against NSDL (the National Numbering Agency). You need it to hold or transfer these unlisted shares in your NSDL or CDSL demat account.
S3V Vascular Technologies is an Indian medical device company that develops and manufactures cardiovascular and critical-care products. Its portfolio includes drug-eluting and bare-metal stents, PTCA and neurovascular catheters, balloon dilatation systems, and other interventional devices, produced through an integrated in-house research and manufacturing model based in Mysore, Karnataka.
No. S3V Vascular Technologies is not currently listed on the NSE or BSE main board; it is a privately held, pre-IPO company whose shares trade in the unlisted market. Unlisted shares are generally bought through an over-the-counter transaction facilitated by an unlisted-shares dealer, with the shares transferred into the buyer's demat account after KYC and settlement. This is informational only and not a recommendation to transact.
Because the shares are not exchange-traded, there is no continuous official market price. The indicative price reflects negotiated demand and supply among buyers and sellers in the unlisted market, and it can differ across counterparties and dates. Factors that participants commonly reference include the company's financial performance, product pipeline, regulatory approvals, funding activity, and broader sentiment around any potential public listing.
S3V Vascular Technologies Limited carries CIN U33112KA2011PLC059915 and ISIN INE0HGT01012. It was incorporated in 2011, has a face value of ₹10 per share, and is registered in Mysore, Karnataka. These are factual identifiers; investors should review the company's latest audited financials and disclosures before forming any view.
They can. If the company declares a dividend, unlisted shareholders are eligible like any other shareholder. Many unlisted firms reinvest profits, so dividends are not guaranteed.
After listing, unlisted shares convert into regular listed shares in your demat account and can be traded on the exchange, usually once any applicable SEBI lock-in period ends.
Unlisted shares are less liquid than listed shares. You can sell when a buyer is available through an off-market transfer; there is no continuous exchange market, so exits can take longer.
Unlisted shares carry higher risk and lower liquidity than listed shares, with fewer disclosures and no live market price. This is general information, not investment advice — assess suitability before investing.
An unlisted share price is an indicative, over-the-counter reference set by demand and supply in private deals between buyers and sellers. There is no live exchange quote, so prices can vary across dealers and over time.
Yes. Unlisted shares are delivered in dematerialised form, so you need an active demat account (NSDL or CDSL). No special account type is required — a regular demat account works.
Unlisted shares are sold through an off-market transfer to a buyer via a registered intermediary, settling from your demat account with a contract note. Liquidity depends on buyer availability, so exits can take longer than listed shares.
S3V Vascular Technologies Limited vs similar unlisted Healthcare shares
Indicative over-the-counter prices, as of 16 July 2026. Information only — not a recommendation or ranking.